Jon S. Saxe's most recent trade in VistaGen Therapeutics Inc was a trade of 17,600 Non-Qualified Stock Option (right to buy) done . Disclosure was reported to the exchange on Sept. 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Sep 2025 | 17,600 | 17,600 | - | - | Non-Qualified Stock Option (right to buy) | |
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Sep 2024 | 14,100 | 14,100 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2024 | 12,500 | 12,500 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Mar 2021 | 2,500 | 0 | - | - | Stock Option (Right to Buy) | |
| VistaGen Therapeutics Inc | Jon S. Saxe | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.50 per share. | 19 Mar 2021 | 2,500 | 5,751 (0%) | 0% | 1.5 | 3,750 | Common Stock |